GlassScriptPhysician profile
Skyler Dungan
NPI 1689482895
$1,217.43
in general payments reported to CMS, 2019-2025
14 companies · $1,155 in 2025
The $1,155 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $61.95 · 2025: $1,155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $982 · Travel and Lodging: $200 · Education: $36.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $981.74 |
| Travel and Lodging | $199.69 |
| Education | $36.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $437.46 | 2025 | Interstim |
| Sumitomo Pharma America, INC. | $213.09 | 2025 | Gemtesa, Orgovyx |
| Janssen Biotech, INC. | $154.89 | 2025 | Erleada |
| Bayer Healthcare Pharmaceuticals INC. | $136.94 | 2025 | |
| Accord Healthcare, INC. | $50.16 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.55 | 2024 | Xifaxan |
| Dendreon Pharmaceuticals LLC | $36.10 | 2025 | Provenge |
| Coloplast Corp | $26.24 | 2025 | |
| Merck Sharp & Dohme LLC | $24.65 | 2025 | Keytruda |
| Pacira Pharmaceuticals Incorporated | $23.16 | 2025 | Exparel |
| Boston Scientific Corporation | $19.14 | 2025 | Ams 700 |
| Tolmar, INC. | $18.08 | 2025 | Eligard, Jatenzo |
| Novo Nordisk INC | $17.40 | 2024 | Rybelsus |
| 180 Medical, INC. | $15.57 | 2025 | Gentlecath |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Skyler Dungan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.